News Seattle Genetics halts trials of latest ADC after safety war... Monitoring committee concerned about high death rates.
Articles Meeting the needs of cancer patients and healthcare provider... Complex and evolving cancer treatment pathways require comprehensive and tailored support programmes.
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News LifeArc spends Keytruda cash on R&D ignored by pharma Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
Views & Analysis Immunotherapies in oncology: the future of cancer treatment ... Partnerships, co-marketing and the positioning of drugs are shaping the competitive landscape in oncology.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
